{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:40:05Z","timestamp":1789501205684,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.intimp.2015.03.047","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T23:27:30Z","timestamp":1428622050000},"page":"897-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Morgan E.","family":"Wallace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marice B.","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kannourakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart P.","family":"Berzins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.03.047_bb0005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2010-07-155663","article-title":"Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities","volume":"117","author":"Chiorazzi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0268-960X(95)90015-2","article-title":"The pathology of the chronic lymphocytic leukaemias","volume":"9","author":"Kroft","year":"1995","journal-title":"Blood Rev."},{"key":"10.1016\/j.intimp.2015.03.047_bb0020","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1172\/JCI64101","article-title":"Molecular pathogenesis of chronic lymphocytic leukemia","volume":"122","author":"Gaidano","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2015.03.047_bb0025","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1172\/JCI66307","article-title":"Lymphocytic malignancies: many tumor types, many altered genes, many therapeutic challenges","volume":"122","author":"Dalla-Favera","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2015.03.047_bb0030","article-title":"Chronic lymphocytic leukemia","volume":"163\u201383","author":"Byrd","year":"2004","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.intimp.2015.03.047_bb0035","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","article-title":"The clinical application of monoclonal antibodies in chronic lymphocytic leukemia","volume":"116","author":"Jaglowski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1182\/asheducation-2010.1.77","article-title":"Prognostic markers and stratification of chronic lymphocytic leukemia","volume":"2010","author":"Furman","year":"2010","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.intimp.2015.03.047_bb0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.intimp.2015.03.047_bb0050","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1158\/1078-0432.CCR-11-2630","article-title":"Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression","volume":"18","author":"Nunes","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2015.03.047_bb0055","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2015.03.047_bb0060","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2015.03.047_bb0065","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1179\/102453312X13336169156410","article-title":"Improving treatment for patients with chronic lymphocytic leukemia","volume":"17","author":"Shanafelt","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2015.03.047_bb0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2013-08-518183","article-title":"CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia","volume":"123","author":"te Raa","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0075","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0080","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2007-08-108605","article-title":"CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment","volume":"111","author":"Patten","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0085","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.celrep.2013.07.011","article-title":"Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells","volume":"4","author":"Os","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2015.03.047_bb0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0145-2126(01)00194-1","article-title":"T type 1\/type 2 subsets balance in B-cell chronic lymphocytic leukemia\u2014the three-color flow cytometry analysis","volume":"26","author":"Podhorecka","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.intimp.2015.03.047_bb0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1189\/jlb.0211069","article-title":"Editorial: CD38 and retinoids: a step toward a cure","volume":"90","author":"Malavasi","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0100","doi-asserted-by":"crossref","first-page":"827","DOI":"10.4049\/jimmunol.1401350","article-title":"Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-gamma by a T-bet-dependent mechanism","volume":"194","author":"Burgler","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0105","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1084\/jem.176.5.1319","article-title":"Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression","volume":"176","author":"Dancescu","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2015.03.047_bb0110","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.leu.2402783","article-title":"IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells","volume":"17","author":"Levesque","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2015.03.047_bb0115","doi-asserted-by":"crossref","first-page":"e78091","DOI":"10.1371\/journal.pone.0078091","article-title":"Th17\/IL-17A might play a protective role in chronic lymphocytic leukemia immunity","volume":"8","author":"Hus","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2015.03.047_bb0120","first-page":"1128","article-title":"Increased frequencies of Th17 in the peripheral blood of patients with chronic lymphocytic leukemia: a one year follow-up","volume":"30","author":"Tang","year":"2014","journal-title":"Pak. J Med Sci"},{"key":"10.1016\/j.intimp.2015.03.047_bb0125","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3324\/haematol.2011.047316","article-title":"Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance","volume":"97","author":"Jain","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2015.03.047_bb0130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Jadidi-Niaragh","year":"2013","journal-title":"Tumour Biol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0135","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12401","article-title":"Enhancement of CD154\/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia","volume":"162","author":"Ahearne","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0140","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4110\/in.2009.9.6.209","article-title":"The role of regulatory T cells in cancer","volume":"9","author":"Ha","year":"2009","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2015.03.047_bb0150","first-page":"52","article-title":"Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander?","volume":"3","author":"D'Arena","year":"2013","journal-title":"Am J Blood Res."},{"key":"10.1016\/j.intimp.2015.03.047_bb0155","first-page":"677","article-title":"Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia","volume":"20","author":"Giannopoulos","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.intimp.2015.03.047_bb0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1365-2249.2011.04466.x","article-title":"Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells","volume":"166","author":"Piper","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0165","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.leukres.2010.08.010","article-title":"Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease","volume":"35","author":"D'Arena","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.intimp.2015.03.047_bb0170","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.anndiagpath.2007.08.002","article-title":"Pathology of chronic lymphocytic leukemia: an update","volume":"11","author":"Inamdar","year":"2007","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0175","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri1309","article-title":"NKT cells: what's in a name?","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nri2904","article-title":"Presumed guilty: natural killer T cell defects and human disease","volume":"11","author":"Berzins","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0185","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri2116","article-title":"Control points in NKT-cell development","volume":"7","author":"Godfrey","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0190","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2015.03.047_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","article-title":"Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy","volume":"175","author":"Chan","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0200","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1007\/s12032-012-0262-4","article-title":"Reduced frequency of NKT-like cells in patients with progressive chronic lymphocytic leukemia","volume":"29","author":"Jadidi-Niaragh","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0205","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3324\/haematol.2012.072835","article-title":"Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy","volume":"98","author":"Weinkove","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2015.03.047_bb0210","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nri3725","article-title":"Natural killer T cells: drivers or passengers in preventing human disease?","volume":"14","author":"Berzins","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0215","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ijc.11723","article-title":"CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes","volume":"109","author":"Fais","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2015.03.047_bb0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-immunol-032713-120243","article-title":"Biology of CD1- and MR1-restricted T cells","volume":"32","author":"Salio","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0225","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.it.2011.02.005","article-title":"Mucosal-associated invariant T cells: unconventional development and function","volume":"32","author":"Le Bourhis","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0230","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.03.047_bb0235","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature11605","article-title":"MR1 presents microbial vitamin B metabolites to MAIT cells","volume":"491","author":"Kjer-Nielsen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2015.03.047_bb0240","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/intimm\/dxn111","article-title":"Invariant Valpha7.2-Jalpha33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells","volume":"20","author":"Peterfalvi","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0245","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ni.1890","article-title":"Antimicrobial activity of mucosal-associated invariant T cells","volume":"11","author":"Le Bourhis","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0250","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2013.00511","article-title":"B cells modulate mucosal associated invariant T cell immune responses","volume":"4","author":"Salerno-Goncalves","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0255","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0260","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2015.03.047_bb0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.intimp.2013.05.021","article-title":"Tumor-induced host immunosuppression: special focus on CLL","volume":"17","author":"Cutucache","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2015.03.047_bb0270","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.autrev.2011.11.018","article-title":"Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells","volume":"11","author":"Kessel","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.047_bb0275","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T02:24:07Z","timestamp":1566527047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915001496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1567576915001496"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.047","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An emerging role for immune regulatory subsets in chronic lymphocytic leukaemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}